key: cord-1026710-4031fpa9
authors: Vaillant, Marie-France; Agier, Lydiane; Martineau, Caroline; Philipponneau, Manon; Romand, Dorothée; Masdoua, Virginie; Behar, Marie; Nesseler, Charlotte; Achamrah, Najate; Laubé, Véronique; Lambert, Karine; Dusquesnoy, Maèva-Nauli; Albaladejo, Laura; Lathière, Thomas; Bosson, Jean-Luc; Fontaine, Eric
title: Food intake and weight loss of survival inpatients in the course of COVID-19 infection
date: 2021-07-27
journal: Nutrition
DOI: 10.1016/j.nut.2021.111433
sha: 1b71d3f7979aeb153155a70ebf1046cca00416cc
doc_id: 1026710
cord_uid: 4031fpa9

NutriCoviD30 is a longitudinal multicenter cohort study that aimed to provide nutritional objective data of inpatients during COVID-19 infection. Food intake and weight trajectories, as well as clinical signs of the disease, pre-existing chronic diseases, and nutritional strategies were collected and analyzed during the course of the disease. Their association was estimated using mixed-effect regression modeling. Patients were recruited from French university hospitals from May until July 2020. For the 403 included patients (mean age 62.2 ± 14.2 years; 63% males), median [interquartile] hospitalization duration was 13 days [8; 20], and 30% of patients were admitted in intensive care unit. Patients declared a median 70% food intake decrease in the acute phase, and the disease resulted in an average loss of 8% of the pre-disease weight (corresponding to -6.5 kg). While most patients recovered their usual food intake one month after hospital discharge, they only regained half of their weight loss, such that malnutrition, which affected 67% of patients during their hospitalization, persisted in 41% of them. Patients with overweight, obesity and diabetes reported an additional weight loss of over 1.5% of their initial bodyweight during the hospitalization and recovery phase. In order to prevent malnutrition and its long-term effect, mainly combined with a rapid weight loss predominantly affecting lean body mass, implementation of nutritional support is needed for COVID-19 inpatients. It should start early in the course of the infection, and be extended up to the recovery phase.

The sudden onset of the coronavirus SARS-CoV-2 has caused organizational upheavals and challenges in managing the current COVID-19 epidemics worldwide. Nutritional care is one of the key aspects of patients' management in situations of serious infection. In communityacquired pneumonia for instance, malnutrition is known to affect the long term recovery and to increase one-and two-year mortality in survived patients, especially for the elderlies 1 .

Given the effect of SARS-CoV-2 on patients taste and appetite 2 , as well as on anosmia, ageusia, diarrhea, odynophagia, and anorexia 3 , 4 , COVID-19 patients are particularly at risk of undernutrition. This risk is often heightened by hospitalization 5 , 6 .

Reports of dramatic weight loss during this epidemic outbreak have led the European 7 , American 8 , and French-speaking 9 learned societies of nutrition to issue expert opinions and recommendations for the nutritional management of patients. Despite this advice, and in the face of the short-term respiratory emergency, nutritional care has received limited attention from clinicians during the initial pandemic wave of the infection.

The aim of this study was to describe the nutritional impact of COVID-19 infection on adult inpatients on the short-to mid-term (up to 30 days after hospital discharge), using food intake and weight measurements. It also aimed to identify factors associated with a decrease in food intake and weight. While SARS-CoV-2 is an emerging and developing disease, this study is expected to improve the understanding of malnutrition in COVID-19 inpatients, and to help clinicians preventing the occurrence and long-term effects of this side effect of the disease.

The NutriCoviD30 study was designed as a prospective multicenter cohort of adult inpatients that were hospitalized with a confirmed COVID-19 infection, and who returned home after hospitalization. Patients were recruited from 11 French university hospitals from May 7 to July 10, 2020, after ethical clearance from the French Committee for the Protection of Persons North West IV.

Patients were called by a nutritionist, medical doctor or dietician, 30 days after hospital discharge. Data was collected in the medical records or during this phone interview, regarding:

1/ prior chronic disease, lifestyle and eating habits before the disease (referred to as t0) 2/ COVID-19 symptoms, hospital stay and nutritional care characteristics during hospitalization (referred to as t1) 3/ World Health Organization (WHO) performance status score, persistence of symptoms and nutritional outcomes one month after hospital discharge (referred to as t2). Appetite assessment can be evaluated with a 10-point visual analogue scale 10 , 11 . Food intake was assessed at t1 and t2 using the 10-point verbal form of the SEFI® scale (Self-Evaluation of Food Intake) scored from 0 ("I eat nothing") to 10 ("I eat as usual"). This scale has been validated and showed good reliability for the assessment of food and energy intake, and malnutrition among adults 12 , 13 , 14 .

Weight assessment was based on patients' declaration at t0 (considered as the reference weight) and t2. The lowest weight during the acute phase of the disease (reported by the patient or during hospitalization) was used as weight at t1. Weight loss at t1 and t2 were defined in terms of proportion of the reference weight at t0.

Quantitative parameters were described by their mean ± standard deviation, or by their median [25 th ; 75 th ] percentiles, depending on the normality of the data. Qualitative parameters were expressed in numbers and percentages. A two-sided P ≤ 0.05 was considered statistically significant.

SEFI® and weight were compared between two time points, between two groups, and between more than two groups (i) if the variable was normally distributed using Student paired test, Student test, and ANOVA, respectively; (ii) if the variable was not normally distributed using Wilcoxon matched-pairs signed-ranks tests, Wilcoxon signed-ranks tests, and Kruskall-Wallis tests, respectively.

Mixed-effect regression modeling was used to study the evolution of SEFI® at t1 and t2, with subjects nested within centers being modeled as random effects. Data from the Parisian hospital centers of Saint-Antoine, Tenon, and Paul Brousse were aggregated due to their small population sizes. Measures at t0 were not included in the model, because they were considered constant among patients and equal to 10, i.e. "I eat as usual".

Weight loss at t1 and t2 was analyzed similarly (weight loss at t0 was null for all patients), with the following adjustment factors being additionally included in the model: the number of days in intensive care unit (ICU) (coded as "0 days", "1 to 7 days", "8 to 15 days", and "more than 15 days") and the admission in post-acute rehabilitation (PAR) unit (yes/no), which are expected to efficiently reflect disease severity; and edema status (coded as "appeared", "disappeared", or "did not change" since the previous period) which has a direct impact on weight. Adjustment factors were implemented with independent fixed effects at t1 and t2.

Mixed modeling can cope with partly missing data at the individual level. The analyses were ran on 402 (99.7%) patients for SEFI® (including 2 patients with one missing data at t1 or t2); and on 386 (95.8%) patients for weight loss (including 86 patients with one missing data).

The following COVID-19 potentially influential factors were further tested one by one: for their association with SEFI® and with weight loss evolution, pre-existing chronic conditions, clinical signs of the disease, and implementation of nutritional strategies. Alike adjustment factors, they were modeled with an independent fixed effect at t1 and t2. If the factor only referred to one period (e.g. to the hospitalization period), the model was fitted only over this period, without a subject random effect.

All data were processed and analyzed using Stata v15.1 (Stata Corporation 4905 Lakeway Drive College Station, TX 77845 USA) and R version 3.3.3 (https://cran.r-project.org/).

A total of 1584 adult inpatients were screened in COVID-units, 945 were eligible and 403 were finally recruited in the present study. Of those not included, half of them did not answer to our call or message. Other reasons are listed in Supplementary Figure 1 .

Patients were on average 62.2 ±14.2 years old; 63% were males ( Table 1) . Regarding chronic diseases, 80% of them presented with one or more chronic conditions ( Table 2 ).

Our study population had an average reference weight (i.e. before the disease) of 83.4 kg ±17.3, and an average body mass index (BMI) of 28.8 kg/m 2 ±5.3.

Three hundred eleven (80%) patients considered their weight stable prior to the disease.

Under 3% of patients were at risk of malnutrition, based on BMI <18.5 kg/m 2 for patients under 70y, and BMI<21 kg/m 2 for patients over 70y.

Patients were hospitalized for a median duration of 13 days. A third were admitted in ICU (median duration: 10 days).

Regarding oxygen requirement, 20% of patients did not receive oxygen, 34% had oxygen therapy ≤3l/min, 27% had oxygen therapy >3l/min, and 19% were intubated ( Patients massively reported COVID-19 symptoms ( Table 2 ).

Only 5% of patients were still on oxygen therapy one month after hospital discharge. Fatigue persisted in 39% of our patients; other symptoms persisted in 10 to 27% of affected patients.

Changes in diet were reported by a third of patients, mainly towards a balanced diet or a diet adapted to COVID-19 symptoms (i.e. split, enriched, or adapted meals to the patient taste modifications).

General recovery was assessed using WHO performance status score. The median score was 1 [0. 25 ; 2] , corresponding to patients that were restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature ( Table 3 ).

SEFI® and weight trajectories are illustrated in Figure 1 . Only 5% of patients neither reported a weight loss ≥5% of their reference weight before the disease, nor a food intake decrease greater than 30% of usual food intake during the course of the disease.

At t1, the median [interquartile] SEFI® was 3 [1; 5] (representing a decrease of 70% of patients' usual food intake), and the average weight decreased to 77 kg ± 16. This represents a weight loss of 6.5 kg ± 5.4 (maximum of 30kg), and a 7.6% ± 5.9 decrease compared to the reference weight (maximum of 32%). Based on etiologic and phenotypic diagnosis criteria, i.e. acute disease and weight loss (from the International Global Leadership Initiative on Malnutrition (GLIM) 15 and French Health Authorities guidelines), 67% patients were malnourished (of whom 42% were severely malnourished).

During the recovery phase (t2), 62% patients recovered their initial SEFI® (i.e. a score of 10), and 19% even reported better appetite than before the disease. Yet a quarter of patients were not hungry when lunch or dinnertime came ( Table 3) .

While the majority of patients regained weight during recovery, our population still recorded an average weight loss of 4.2% ± 5.0 of their reference weight one month after hospital discharge (i.e. -3.8 kg ± 4.7) ( Table 1) , indicating that 41% patients remained malnourished (of whom 25 % were severely malnourished).

Among the 49% patients that did not recover their initial weight, 62% declared they did so voluntarily.

Mixed models confirmed a significant difference between t1 and t2 in SEFI®, and in weight loss, after adjusting for patients and recruitment center variability, and the selected set of adjustment factors: SEFI® regression coefficient was 3.4 at t1 and 8.9 at t2; weight loss coefficient was 6.1% at t1 and 3.4% at t2. As per the adjustment factors, the duration of stay in ICU displayed a significant association with a greater weight loss (6.9% at t1 and of 4.3% at t2 for patients who spent more than 15 days in ICU compared those who were not admitted in ICU, both p<0.001); while PAR stay and edema status were in global not further associated with weight loss at t1 and t2 (Supplementary Table 2 ). In our population, age was not associated with differences in weight loss (Supplementary Table 3) .

We further screened for an additional effect of COVID-19 potentially influential factors, one by one ( Table 2 and Table 4 ). Regarding SEFI®, chronic diseases had no impact at t1 and t2, except for chronic respiratory diseases which were associated with a 0.7 point decrease in SEFI® at t2 (p=0.026).

All the symptoms of COVID-19 were associated with a statistically significant decrease in SEFI® at t1 (of 0.5 to 3.6 points, all p <0.045). The strongest associations were observed for anorexia and fatigue ( Table 2) . Difficulties drinking, food disgust, anorexia, and painful mouth remained associated with a significant decrease in SEFI® at t2, but of lower magnitude compared to t1 (0.5 to 0.8 points, all p<0.025).

Regarding weight loss, only fatigue (p=0.003), anorexia (p=0.006), and food disgust (p=0.013) were significantly associated with a weight loss at t1 (with, respectively, a 2.3%, 1.8% and 1.3% greater weight loss compared to those who did not display such symptoms).

None were significantly associated with weight loss at t2.

Among the chronic diseases, diabetes was significantly associated with a 1.8% (p=0.004) and

1.5% (p=0.026) increased weight loss at t1 and t2, respectively; hypertension was associated with a 1.4% increased weight loss at t2 (p=0.018). Overweight (BMI between 25 to 30 kg/m 2 ) and obesity (BMI>30 kg/m 2 ) were associated with a greater weight loss compared to patients with a normal BMI (18.5 to 25 kg/m 2 ), of respectively 1.6% and 2.2% at t1, and 1.7% and 3.7% at t2 (all p<0.020).

In terms of nutritional strategies, half of the population took oral nutritional supplements (ONS) during their hospitalization, for a median of 8 days, and 14 units in total; and 30% of the patients were prescribed ONS after returning home, for a median 60 units in total. During their hospitalization, 61% of patients received adapted meals (i.e. different from the standard meal, corresponding to enriched meals or texture-modified food) and 49% received snacks.

Nutritional care data during hospitalization and the recovery phase does not include artificial nutrition due to their non-exhaustive collection in several centers.

Using mixed models (Table 3 and 4) , none of these strategies were found to be significantly associated with SEFI® or weight loss, except for advices given by a nutritionist that were associated at t1 with a 1.2% increased weight loss (p=0.007), and ONS that were associated with a 1.6% weight gain at t2 for patients who were prescribed ONS at home (p=0.001).

Despite the fact that there was no interventional group, we compared patients who received, or not, ONS during their hospitalization ( Table 5 ). The 196 patients who were prescribed ONS had lost more weight at t1 than the 189 patients who did not receive ONS (p-value <0.001). However, they recovered better at hospital discharge and at 1 month from hospital discharge (p-value = 0.0005 and 0.009, respectively). Note that the two groups did not differ in terms of sex ratio, pre-disease weight, or SEFI® at t1, whereas the ONS group was older.

In our population of 403 inpatients who survived the COVID-19 infection, 67% suffered from malnutrition (defined by a weight loss greater than 5% within the past 6 months in a population of infected patients). Other studies 11, 16 using the same malnutrition definition reported an overall prevalence of malnutrition of 31% and 42.1%, respectively. Another study 6 reported 52.7% malnutrition based on Mini Nutritional Assessment score. These differences result in great part from differences in the study populations, typically in terms of gravity of the disease. For instance, 3% of the 156 inpatients were admitted in ICU in Di Filippo and al. study 11 , 16% of the 114 inpatients in Bedock and al. study 16 , while it affected 30% of the 403 inpatients in the present study (data not available in Li and al. 6 ).

As previously reported 17,18 , we found that anorexia, fever, dyspnea and fatigue were the most prevalent clinical features of COVID-19. Fatigue, anorexia and food disgust were major aggravating factors for weight loss in the acute phase of the disease, along with chronic diabetes, overweight, and obesity. Unsurprisingly, we found that the more severe the disease (as reflected by the number of days spent in ICU), the greater the weight loss.

Distinguishing our work from previous studies, we aimed to understand the recovery process, to investigate breaks on regaining weight and on recovering a normal food intake, as well as to assess the impact of nutritional strategies. The observed decrease in food intake is likely an immediate consequence of the infection-related anorexia and food disgust, it was transient;

unlike the COVID-19 impact on weight.

As a matter of fact, 41% of our patients still suffered from malnutrition one month after returning home. This suggests that rapid weight loss is a major side effect which likely predominantly affects muscle mass. Interestingly, a substantial proportion of our patients voluntarily did not aim to recover their initial weight. These were predominantly patients with overweight or obesity, who were happy with their weight loss. This observation highlights the risk for patients with obesity and sarcopenia, as warned by Barazzoni and al. 19 , to be more conscious of public health messages regarding the benefits of losing weight, than of the importance of preserving their muscle mass and function. In line with the European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO) 19 , and the European Society of Endocrinology 20 , this leads us to call for particular attention to this population. Adults with diabetes should also benefit from an acute surveillance, as they tend to lose more weight than other patients 21 .

The benefit of nutritional strategies during hospitalization (encouragement to eat, fortified food, etc.) is likely biased by the fact that nutritional supports were predominantly given to the patients most affected by the disease (i.e. those who had the greatest drop in appetite and weight). For instance, patients receiving ONS had lost more weight than patients without ONS.

Disentangling this confounding effect from the effect of a nutritional strategy would have required an intensive follow-up of patients during the acute phase (i.e. routine measures of weight and energy intake), which was not possible during the first epidemic wave when health professionals were overloaded. Consequently, the results at t1 should be interpreted with great caution.

On the contrary, the results obtained during the recovery phase are probably not affected by this confounding effect (all patients were in recovery during this period). Interestingly, ONS were significantly associated with a weight gain at t2. This observation is in favor of guidelines for COVID-19 22 stating that meals and snacks should be adapted to patients disgusts and capabilities 23 and combined with resisted physical exercise 24 . This is also in agreement with Caccialanza and al. 25 who recommended two or three bottles of ONS for noncritically ill patients as a systematic prescription for patients with nutritional risk. Note however, that this study was not randomized. Consequently, further interventional studies are needed to confirm our results.

The strength of the NutriCoviD30 study design lies in collecting repeated SEFI® and body weight measures during the course of the COVID-19 infection, i.e. before the disease, during the hospitalization and 1 month after hospital discharge. When analyzing food intake and weight loss trajectories using linear mixed models, individual characteristics affecting the measure (eg. educational status) are accounted for by the individual random effect, as long as they do not differentially impact the three periods.

There are however several limitations to our study. First, our population consisted only of inpatients survivors. This excludes the most severe inpatients who were still hospitalized or in PAR units at the time of the study, and the less severe patients who did not require to be hospitalized.

A second limitation relates to weight measurements. Its assessment was not complete. At the highest, 98 patients did not provide a weight measure at t2, because of no bathroom scale at home, or because they refused to weigh themselves. Additionally, weighting accuracy depends on the scales tuning, which is expectedly equally affected by positive and negative calibration fluctuations. Hence, weights are measured with a between-person random error, resulting in unbiased estimates of the average weight 26 . Yet, the variance is inflated, which can lower statistical power in mixed models. Finally, the consistency observed between weight measurements (Supplementary Table 4 ) gives us confidence in the data and analyses we reported.

The use of SEFI® relies on declarative assessment which is less precise than a professional evaluation or measuring energy intake. Yet, our interest lies in the SEFI® trajectories, and was investigated using models that account for inter-individuals differences and focuses on intra individual variations between measures. For people with moderate cognitive decline (3% , Table 2 ), a relative helped to answer the questionnaire during the interview.

To our knowledge, NutriCoviD30 is the largest multicenter longitudinal cohort studying the nutrition of hospitalized patients with COVID-19 infection to date. Its main interest lies in assessing malnutrition on the mid-term, i.e. including the recovery phase up to 1 month after hospital discharge. This study provides a description of COVID-19 symptoms, and of preexisting chronic conditions, as well as their potential impact on the patients' food intake and weight loss. It also describes and investigates the nutritional interventions implemented during the infection and recovery phase.

COVID-19 resulted in a substantial weight loss in inpatients, which rapidity infers that it affected the muscle mass much more than the fat mass. Patients only regained half of their weight loss one month after hospital discharge, even though their food intake went back to normal. Malnutrition affected 67% of patients during their hospitalization and persisted for 41% of them one month after hospital discharge. This is partly due to patients not being aware of the severity of muscle wasting during rapid weight loss. The mid-to long-term effects of Weight loss values (as a percentage of weight at t0) were grouped into classes: none: <5%, medium: [5%; 10%[, and severe weight loss: ≥10%. Weight loss at t0 was 0 for all patients.

Food intake values were grouped into classes: normal: [0;3[, low: [3,7[ , and very low food intake: [7, 10] . SEFI at t0 was assumed to be 10 for all patients.

Graphs are ordered by decreasing number of patients per trajectory type.

The thicker and darker the line, the greater the number of patients with this trajectory. a Amongst non-missing data. N(%) is used for qualitative data; mean (standard deviation) for normally distributed quantitative data (based on data visualization); and median [inter-quartile range] for non-normal quantitative data. b Amongst patients who had this symptom at t1 c Amongst the 148 patients who adapted their diet after COVID-19 infection. Diet adaptation is a strategy to fight or a consequence of COVID-19 infection. It consists of split meals, enriched food, or increased protein intake. Diet alteration consists of a decreased food intake due to a loss of appetite, or a loss/change in taste. WHO: World Health Organization, SEFI®: Self-Evaluation of Food Intake 

Prognostic significance of malnutrition for long-term mortality in community-acquired pneumonia: a propensity score matched analysis

Viral infection and smell loss: The case of COVID-19

Potential pathogenesis of ageusia and anosmia in COVID-19 patients

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Malnutrition and its impact on cost of hospitalization, length of stay, readmission and 3-year mortality

Prevalence of malnutrition and analysis of related factors in elderly patients with COVID-19 in Wuhan, China

ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection

Nutrition Therapy in Critically Ill Patients With Coronavirus Disease

Stratégie de prise en charge nutritionnelle à l'hôpital au cours de l'épidémie virale Covid-19 : avis d'experts de la Société Francophone de Nutrition Clinique et Métabolisme (SFNCM)

COVID-19 is associated with clinically significant weight loss and risk of malnutrition, independent of hospitalisation: A post-hoc analysis of a prospective cohort study

Use of 10-point analogue scales to estimate dietary intake: a prospective study in patients nutritionally at-risk

A visual analogue scale for food intake as a screening test for malnutrition in the primary care setting: Prospective non-interventional study

The self evaluation of food intake SEFI® is feasible and diagnoses malnutrition in the older people living in a nursing home

GLIM criteria for the diagnosis of malnutrition -A consensus report from the global clinical nutrition community

Prevalence and severity of malnutrition in hospitalized COVID-19 patients

Comorbidities and multi-organ injuries in the treatment of COVID-19

COVID-19 and endocrine diseases. A statement from the

Association between sarcopenic obesity and higher risk of type 2 diabetes in adults: A systematic review and meta-analysis

Malnutrition Care During the COVID-19

Pandemic: Considerations for Registered Dietitian Nutritionists

Providing nutritional support for the patient with COVID-19

Effects of protein supplementation combined with resistance exercise on body composition and physical function in older adults: a systematic review and meta-analysis

Early nutritional supplementation in noncritically ill patients hospitalized for the 2019 novel coronavirus disease (COVID-19): Rationale and feasibility of a shared pragmatic protocol

Systematic review of statistical approaches to quantify, or correct for, measurement error in a continuous exposure in nutritional epidemiology

0.303 (Wilcoxon test) ** p-value<0.01 * p-value<0.05 a Amongst non-missing data. N(%) is used for qualitative data; mean (standard deviation) for normally distributed quantitative data (based on data visualization); and median [inter-quartile range] for non-normal quantitative data. SEFI®: Self-evaluation of food intake scale 

☐ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.X The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: